Genmab A/S (OTCMKTS:GNMSF) Sets New 12-Month High - Here's Why

Key Points

• Genmab A/S shares reached a new 52-week high of $286.50, rising from a previous close of $282.00, with 473 shares traded.
• The company reported earnings of $5.42 per share, significantly exceeding estimates of $3.99, despite revenue falling short of expectations at $925 million.
• Genmab specializes in antibody therapeutics for cancer treatment, including products like DARZALEX for multiple myeloma and teprotumumab for thyroid eye disease.

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $286.50 and last traded at $286.50, with a volume of 473 shares traded. The stock had previously closed at $282.00.

Genmab A/S Trading Up 1.6%

The firm has a market cap of $18.93 billion, a P/E ratio of 14.38 and a beta of 0.90. The business has a 50-day moving average of $244.39 and a two-hundred day moving average of $217.21.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping the consensus estimate of $3.99 by $1.43. The company had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.